Selexis SASelexis SA
  • Services
    • Overview
    • Cell Line Development
    • Lead Identification
    • Genome Characterization
    • GENE to GMP
  • Technology
    • Overview
    • Gene Technology and Procedures – Recombinant Protein Production with CHO Cells
    • Media and Feed Strategies
    • Proprietary CHO-K1 Cell Line
    • Whole-Genome Sequencing
  • Programs
  • Applications
    • Overview
    • Bioproduction
    • Preclinical Production
    • Target Discovery
    • Cell-Based Assays
    • Diagnostics
  • About Us
    • Overview
    • Corporate Leadership
    • Scientific Leadership
    • Board of Directors
    • Company History
    • Business Development
    • Investors
    • Partners
    • JSR Life Sciences
  • Newsroom
    • Latest News
    • Archives
    • Calendar
    • Media Contact
    • Press Kit
    • Xpressions Blog
  • Careers
    • Overview
    • Open Positions
    • Great Place to Work
    • Submit Resume
  • Contact

Best-in-Class Cell Line Development and Biologic Manufacturing Coming Together

Xpressions Blog: Best-in-Class Cell Line Development and Biologic Manufacturing Coming Together




Best-in-Class Cell Line Development and Biologic Manufacturing Coming Together

Written by Robert Meister on July 17, 2018

The CEOs of Selexis SA and KBI Biopharma Answer Some Common Questions (An interview from BIO 2018)

Selexis CEO Igor Fisch, PhD, and KBI Biopharma President and CEO Tim Kelly, PhD, address the most common questions about being a part of JSR Life Sciences and their new collaboration, GENE to GMP in 9 Months

 

Q. JSR acquired KBI in 2015 and Selexis in 2017. Did you have a history of working together prior to the acquisition?

Igor: Yes. In fact, we engaged in our first partner project, a difficult-to-express bispecific already in in 2012. Since then, we have collaborated on more than 20 programs making a range of products from monoclonal antibodies (mAbs) to bispecifics and fusion proteins. I believe KBI has performed GMP manufacturing with more than 10 of our cell lines.

Tim: That is correct. I also want to point out that, as a result these 20 plus projects, we believe we offer industry-leading titers for a broad range of product types. For monoclonal antibodies, we have achieved titers as high as 9.5 g/L. For bispecifics and fc-fusions, we average >4.3 g/L and 6.4 g/L respectively at bioreactor harvest (see graph below).

GENE to GMP in 9 Months. Reach the clinic faster

Q. You recently launched Gene to GMP in 9 Months. What does Gene to GMP mean?

Igor: Our Gene to GMP service offering brings together the collective expertise of both KBI and Selexis to deliver a seamless process for fast development of protein therapeutics without sacrificing quality or analytics. For conventional mAbs and more readily-expressible proteins, a partner provides us with their gene sequence and we advance the development process all the way to clinical grade API, active pharmaceutical ingredient, in nine months. The Selexis team brings more than 17 years of cell line development technology and experience to this collaboration. With our accelerated research cell bank program, we can generate stable and high expressing RBCs in 14 weeks.

Tim: Dovetailing off of what Igor said about no sacrifice in quality or analytics, at KBI, we are driven by data. We believe that reliable high quality manufacturing can only be achieved with a thorough understanding of the protein at the biochemical and structural level. As a result, we have built deep analytics capabilities in-house that support all aspects of our process development and manufacturing services. In our experience, detailed protein characterization improves decision-making and drives speed in development and manufacturing. Our capabilities perfectly complement Selexis’ expertise, enabling us to work together to bring this important offering to our partners.

Q. Not all proteins are readily expressed or secreted from CHO cells. How do your two organizations work together on difficult-to-express proteins?

Igor: The pressures on CHO cells to express complex and difficult-to-express proteins led us to develop modules for our SUREtechnology Platform that address a range of issues. For example, we developed the SURE CHO-Mplus Libraries to address translation/secretion bottlenecks, SUREvariant Screening for lead candidate selection and, last but not least, SUREscan and SUREsignature for quality assessment and barcoding of the clonal production cell line using next generation sequencing methods.

Tim: Difficult-to-express proteins are often also difficult to purify, and we frequently cannot rely on conventional high-yield affinity chromatography steps such as Protein A. KBI has built exceptionally strong process development capabilities to solve the challenges of the new generation of non-mAb products and successfully deliver these innovative drugs to patients.

Q. What are some the most difficult or complicated projects you have worked on together?

Tim: As we have both mentioned, many of our clients are developing bispecifics and other novel constructs. These products frequently pose significant challenges for both cell line expression and production. Selexis’ track record of achieving industry-best titers for such products is outstanding, and KBI supports this with the high-resolution analytics necessary to ensure the selected clone meets product quality requirements, such as high heterodimer ratio for bispecifics. Together, KBI and Selexis have an exceptional track record of delivering the highest quality process and product for bispecifics under accelerated development timelines.

Q. What do you see in the future for biologics generation and manufacturing?

Igor: Next-generation protein biologics are increasingly complex to manufacture. We are already seeing this with molecules like bispecific t-cell engagers mAbs and immunocytokines that recruit the immune system for cancer control. These complex molecules will push the secretory limits of the current CHO cells. Based on the extensive genomic, transcriptomic metabolomic analysis of our proprietary CHO-K1 cell line, we are continuing to improve our CHO cell line and offer modular solutions to be able to accommodate these newer, non-natural proteins.

Tim: I agree with Igor. We will continue to see increasingly complex molecules that will pose unique challenges for process development, scale-up, and predictable cGMP production. KBI is uniquely qualified to overcome these challenges because of our exceptionally strong and deep analytical and process development capabilities. Today, KBI and Selexis are on the leading edge of novel biologics development and together we are building the foundation for the even more challenging therapeutics of tomorrow.

 

For more information about GENE to GMP in 9 Months, please visit www.GtoG.bio.

For more information about KBI’s analytic and manufacturing capabilities, visit www.kbibiopharma.com.

  • Latest News
  • Archives
  • Calendar
  • Media Contact
  • Press Kit
  • Xpressions Blog
  • Keywords:


    SelexisKBI BiopharmabispecificGMP Manufacturingcell line developmentGENE to GMPanalyticsmonoclonal antibodydifficult-to-expressprotein therapeuticsnext-generation-biologics

    Sitemap

    • Home
    • Services
    • Overview
    • Cell Line Development
    • Lead Identification
    • Genome Characterization
    • GENE to GMP
    • Technology
    • Overview
    • Gene Technology and Procedures
    • Media and Feed Strategies
    • Proprietary CHO-K1 Cell Line
    • Genome and Transcriptome
    • Selexis Online Library
    • Overview
    • Technology Sheets
    • Scientific Publications
    • Scientific Posters
    • White Papers and Articles
    • Videos
    • Fact Sheets
    • Presentations
    • Applications
    • Overview
    • Bioproduction
    • Preclinical Production
    • Target Discovery
    • Cell-Based Assays
    • Diagnostics
    • Programs
    • Licensing
    • Publications
    • Innovation Timeline
    • Technology FAQs
    • About Us
    • Overview
    • Corporate Leadership
    • Scientific Leadership
    • Board of Directors

    • Company History
    • Business Development
    • Investors
    • Partners
    • JSR Life Sciences
    • Newsroom
    • Latest News
    • Archives
    • Calendar
    • Media Contact
    • Press Kit
    • Xpressions Blog
    • Contact Us
    • General Inquiries
    • Corporate Headquarters
    • Careers
    • Overview
    • Open Positions
    • Great Place to Work
    • Submit Resume
    • Legal
    • Privacy
    • Cookies
    • Social Media

    Great Place to Work 2020

    About Selexis

    Selexis SA, a JSR Life Sciences Company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis cell line development technologies to advance more than 115 drug products in clinical development and the manufacture of five commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks.

    JSR Logo

    • Terms of Use
    • Privacy
    • Cookies
    • Social Media
    • LinkedIn
    • Twitter
    • Facebook
    Selexis SA Copyright © . All Rights Reserved.

     

      • Services
        • Overview
        • Cell Line Development
        • Lead Identification
        • Genome Characterization
        • GENE to GMP
      • Technology
        • Overview
        • Gene Technology and Procedures – Recombinant Protein Production with CHO Cells
        • Media and Feed Strategies
        • Proprietary CHO-K1 Cell Line
        • Whole-Genome Sequencing
      • Programs
      • Applications
        • Overview
        • Bioproduction
        • Preclinical Production
        • Target Discovery
        • Cell-Based Assays
        • Diagnostics
      • About Us
        • Overview
        • Corporate Leadership
        • Scientific Leadership
        • Board of Directors
        • Company History
        • Business Development
        • Investors
        • Partners
        • JSR Life Sciences
      • Newsroom
        • Latest News
        • Archives
        • Calendar
        • Media Contact
        • Press Kit
        • Xpressions Blog
      • Careers
        • Overview
        • Open Positions
        • Great Place to Work
        • Submit Resume
      • Contact
      The new European data protection law requires us to inform you of the following before you use our website:

      We use cookies to customize your experience, perform analytics and deliver personalized advertising on our site. By clicking “I agree” below, you consent to the use by us and our third-party partners of cookies and data gathered from your use of our website. See our Privacy Policy to learn more about the use of data and your rights. You also agree to our Terms of Service.


      I AgreeContinue to site
      Privacy & Cookies Policy

      Privacy Overview

      This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
      Necessary
      Always Enabled

      Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

      Non-necessary

      Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

      SAVE & ACCEPT